Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

Brian Bressler, Gerassimos J. Mantzaris, Mark S. Silverberg et al.|Journal of Crohn s and Colitis|2021

Cited by 148